PL2109622T3 - Przeciwciała o wysokim powinowactwie neutralizujące gronkowcową enterotoksynę B - Google Patents

Przeciwciała o wysokim powinowactwie neutralizujące gronkowcową enterotoksynę B

Info

Publication number
PL2109622T3
PL2109622T3 PL08712978T PL08712978T PL2109622T3 PL 2109622 T3 PL2109622 T3 PL 2109622T3 PL 08712978 T PL08712978 T PL 08712978T PL 08712978 T PL08712978 T PL 08712978T PL 2109622 T3 PL2109622 T3 PL 2109622T3
Authority
PL
Poland
Prior art keywords
staphylcoccus
enterotoxin
neutralize
high affinity
affinity antibodies
Prior art date
Application number
PL08712978T
Other languages
English (en)
Polish (pl)
Inventor
Philip M. Sass
Nicholas C. Nicolaides
Luigi Grasso
Marc Berger
Tao Sai
Original Assignee
Morphotek, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphotek, Inc. filed Critical Morphotek, Inc.
Publication of PL2109622T3 publication Critical patent/PL2109622T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Gram-positive bacteria
    • C07K16/1271Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL08712978T 2007-01-03 2008-01-03 Przeciwciała o wysokim powinowactwie neutralizujące gronkowcową enterotoksynę B PL2109622T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88327107P 2007-01-03 2007-01-03
US88840507P 2007-02-06 2007-02-06

Publications (1)

Publication Number Publication Date
PL2109622T3 true PL2109622T3 (pl) 2017-06-30

Family

ID=39529113

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08712978T PL2109622T3 (pl) 2007-01-03 2008-01-03 Przeciwciała o wysokim powinowactwie neutralizujące gronkowcową enterotoksynę B

Country Status (9)

Country Link
US (6) US8236932B2 (https=)
EP (2) EP2109622B1 (https=)
JP (3) JP5412293B2 (https=)
AU (1) AU2008205376B2 (https=)
CA (2) CA2924155C (https=)
DK (1) DK2109622T3 (https=)
ES (1) ES2619943T3 (https=)
PL (1) PL2109622T3 (https=)
WO (1) WO2008085878A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236932B2 (en) 2007-01-03 2012-08-07 Morphotek, Inc. High affinity antibodies that neutralize Staphylococcus enterotoxin B
US20110166076A1 (en) * 2008-09-10 2011-07-07 Bac Ip B.V. Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases
WO2013089877A2 (en) * 2011-09-27 2013-06-20 Albert Einstein College Of Medicine Of Yeshiva University Adjuvant therapy for staphylococcal infection with enterotoxin specific mabs
CN103946236B (zh) * 2011-11-23 2018-02-16 弗·哈夫曼-拉罗切有限公司 表达cd40l的哺乳动物细胞及其用途
US20160039914A1 (en) * 2013-03-14 2016-02-11 Albert Einstein College Of Medicine Of Yeshiva University Humanized antibodies specific for staphylococcal enterotoxin b
EP3532497B1 (en) * 2016-10-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
US20230192896A1 (en) * 2016-11-23 2023-06-22 Bioverativ Therapeutics Inc. Bispecific antibodies binding to coagulation factor ix and coagulation factor x
KR102124258B1 (ko) * 2018-10-19 2020-06-26 대한민국(관리부서 질병관리본부장) 신속 면역크로마토그래피법을 이용한 황색 포도알균 장독소 b 진단·탐지 키트 및 이를 위한 특이항체와 항체생산세포주
EP4051711A4 (en) * 2019-11-01 2024-02-21 Magenta Therapeutics, Inc. ANTI-CD45 ANTIBODIES AND THEIR CONJUGATES
KR102274759B1 (ko) * 2020-01-16 2021-07-09 대한민국(질병관리청장) 황색포도알균 장독소 b에 특이적인 항체 및 이의 용도
CN119101153B (zh) * 2024-04-30 2025-07-08 中国人民解放军军事科学院军事医学研究院 一种葡萄球菌肠毒素b纳米抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2574089A (en) 1948-06-08 1951-11-06 Cochran Jacqueline Luggage case having a removable lining
US4854432A (en) 1988-07-06 1989-08-08 American Tourister, Inc. Suitcase having removable divider with clothing pockets
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
CA2194450A1 (en) 1994-07-06 1996-01-18 Truckin' Movers Corporation Convertible carrying case and work platform
US6036697A (en) 1998-07-09 2000-03-14 Scimed Life Systems, Inc. Balloon catheter with balloon inflation at distal end of balloon
CA2345023A1 (en) 1998-10-07 2000-04-13 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome and septic shock
EP1532175B1 (en) 2002-03-22 2012-10-17 Aprogen, Inc. Humanized antibody and process for preparing the same
US20050240009A1 (en) 2002-08-21 2005-10-27 Carr Francis J T-cell epitopes in staphylococcal enterotoxin b
WO2005023853A1 (ja) * 2003-09-05 2005-03-17 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute プロテアーゼ耐性seb改変体およびそれを含むワクチン
CA2596925C (en) 2005-02-08 2017-07-04 Km Biologics Co., Ltd. Method for improving expression level and stability of antibody
WO2007141274A2 (en) * 2006-06-06 2007-12-13 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
US8236932B2 (en) * 2007-01-03 2012-08-07 Morphotek, Inc. High affinity antibodies that neutralize Staphylococcus enterotoxin B

Also Published As

Publication number Publication date
CA2924155A1 (en) 2008-07-17
EP3138852A1 (en) 2017-03-08
WO2008085878A2 (en) 2008-07-17
AU2008205376A1 (en) 2008-07-17
CA2674382C (en) 2016-05-31
US20170121396A1 (en) 2017-05-04
JP5412293B2 (ja) 2014-02-12
EP2109622A2 (en) 2009-10-21
US9868780B2 (en) 2018-01-16
DK2109622T3 (en) 2017-02-13
US8236932B2 (en) 2012-08-07
US8895704B2 (en) 2014-11-25
AU2008205376B2 (en) 2012-07-12
US20150050276A1 (en) 2015-02-19
JP2013216673A (ja) 2013-10-24
US20180094048A1 (en) 2018-04-05
US8889846B2 (en) 2014-11-18
US20130183314A1 (en) 2013-07-18
WO2008085878A3 (en) 2009-02-26
CA2674382A1 (en) 2008-07-17
JP5881646B2 (ja) 2016-03-09
JP2016146824A (ja) 2016-08-18
US20120171223A1 (en) 2012-07-05
EP2109622B1 (en) 2016-11-09
US9359428B2 (en) 2016-06-07
JP6195946B2 (ja) 2017-09-13
US10364284B2 (en) 2019-07-30
JP2010514459A (ja) 2010-05-06
CA2924155C (en) 2020-02-11
ES2619943T3 (es) 2017-06-27
US20140072553A1 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
PL2109622T3 (pl) Przeciwciała o wysokim powinowactwie neutralizujące gronkowcową enterotoksynę B
GB0708002D0 (en) Antibodies
GB2451928B (en) Modified Toxins
PT2146745E (pt) Anticorpo pentaespecífico
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
IL204615A0 (en) Human antibodies that bind mesothelin, and uses thereof
IL200437A0 (en) Anti-sclerostin antibodies
SI2195026T1 (sl) Protitelesa proti sklerostinu
IL198592A0 (en) Tes7 and antibodies that bind thereto
ZA201002275B (en) Il-23 antibodies
IL201983A (en) Antibody against pan nrpa
ZA200904022B (en) Monoclonal antibodies against ANGPTL3
PT2011869E (pt) Novo anticorpo anti-cd98
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
GB0718737D0 (en) Antibodies
IL205073A0 (en) Anti-bst2 antibody
IL202942A (en) Chromatographic methods
GB0615662D0 (en) Antibody
EP2193144A4 (en) ANTIBODIES TO FLAGELLIN AND APPLICATIONS THEREOF
IL202996A0 (en) Anti-mcp-1 antibodies, compositions, methods and uses
EP1943526A4 (en) DEVICE FOR RESOLVING RELATIONSHIP BETWEEN PEOPLE
GB0707716D0 (en) Affinity group
GB0606276D0 (en) Antibodies
GB0607376D0 (en) Antibodies
GB0724185D0 (en) Antibodies